Henry H. Armstrong Associates’s Novo Nordisk NVO Stock Holding History

Henry H. Armstrong Associates’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$319K	Hold	6,664	–	–	0.03%	52
2026 Q1	$245K	Hold	6,664	–	–	0.03%	55
2025 Q4	$339K	Sell	6,664 -1,544	-19%	-$79K	0.03%	50
2025 Q3	$455K	Sell	8,208 -225	-3%	-$13.2K	0.04%	45
2025 Q2	$582K	Sell	8,433 -591	-7%	-$40.2K	0.05%	42
2025 Q1	$627K	Sell	9,024 -500	-5%	-$41.3K	0.06%	40
2024 Q4	$819K	Hold	9,524	–	–	0.08%	38
2024 Q3	$1.13M	Sell	9,524 -800	-8%	-$107K	0.11%	34
2024 Q2	$1.47M	Hold	10,324	–	–	0.15%	30
2024 Q1	$1.33M	Hold	10,324	–	–	0.13%	33
2023 Q4	$1.07M	Hold	10,324	–	–	0.11%	32
2023 Q3	$939K	Hold	10,324	–	–	0.11%	33
2023 Q2	$835K	Sell	10,324 -500	-5%	-$40.8K	0.09%	35
2023 Q1	$861K	Sell	10,824 -6,586	-38%	-$467K	0.1%	35
2022 Q4	$1.18M	Hold	17,410	–	–	0.15%	34
2022 Q3	$867K	Buy	+17,410	New	+$933K	0.12%	35

Other funds holding NVO

SRIM

Saratoga Research & Investment Management Saratoga, California $1.83B AUM 18.41% 1-Year Est. Return

SAM

Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return

GuoLine Advisory Singapore $1.07B AUM 26.27% 1-Year Est. Return

QV Investors Calgary, Alberta, Canada $1.3B AUM 31.14% 1-Year Est. Return

ABC Arbitrage Paris, France $926M AUM 45.9% 1-Year Est. Return

OFA

Oak Family Advisors Chicago, Illinois $391M AUM 26.35% 1-Year Est. Return

Penbrook Management New York $157M AUM 46.57% 1-Year Est. Return

PFS

Prospera Financial Services Dallas, Texas $6.89B AUM 37.41% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

AIP

ARS Investment Partners New York $2.29B AUM 113.95% 1-Year Est. Return

Henry H. Armstrong Associates's NVO Position: Q2 2026 in Review

Henry H. Armstrong Associates held its Novo Nordisk (NVO) position steady in Q2 2026 at 6,664 shares worth $319K. The position accounts for 0.03% of the portfolio, ranked #52.

Henry H. Armstrong Associates first reported a position in NVO in Q3 2022 and has held it in 16 quarters since. The position peaked at $1.47M in Q2 2024. 379 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

Henry H. Armstrong Associates held 6,664 shares of Novo Nordisk worth $319K as of Q2 2026.
Henry H. Armstrong Associates left its Novo Nordisk share count unchanged in Q2 2026.
Novo Nordisk made up 0.03% of Henry H. Armstrong Associates's portfolio in Q2 2026, its #52 holding.
Henry H. Armstrong Associates first reported a position in Novo Nordisk in Q3 2022 and has held it in 16 quarters since.
Henry H. Armstrong Associates's Novo Nordisk position peaked at $1.47M in Q2 2024.
379 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Henry H. Armstrong Associates's 13F filing for Q2 2026, filed 7 Jul 2026.